文献速递细菌感染、耐药与抗菌药物

熊果叶提取物与磷霉素治疗女性非复杂性尿路感染的随机对照试验

Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial.
PubMed 文献 · Clin Microbiol Infect · 2021-06-07

本研究在德国42家家庭诊所开展双盲随机对照试验,纳入398例成年女性非复杂性尿路感染患者,比较熊果叶提取物(UU)与磷霉素的疗效。结果显示UU组抗生素使用减少63.6%,但症状负担比为136.5%,未达到非劣效性,且肾盂肾炎发生例数数值上更多。

要点

  • 熊果叶提取物初始治疗可显著减少抗生素使用。
  • 但症状负担未达到非劣效标准,且肾盂肾炎发生数数值更高。
  • 非复杂性尿路感染女性不宜以熊果叶提取物替代磷霉素。

核心结论

  • 在非复杂性尿路感染女性中,熊果叶提取物初始治疗减少抗生素使用,但症状负担更高且安全性顾虑多于磷霉素。

研究设计与样本

  • 双盲随机对照试验,在德国42家家庭诊所开展,纳入398例成年女性非复杂性尿路感染患者,随机分为UU组207例和磷霉素组191例。

主要发现

  • UU组抗生素疗程数较磷霉素组低63.6%(95%CI 53.6%-71.4%;p<0.0001)。
  • UU组与对照组总症状负担比为136.5%(95%CI 122.7-151.9;p 0.95),未达到非劣效性。
  • UU组8例发生肾盂肾炎,磷霉素组2例(均数差2.8;95%CI 0.2-5.9;p 0.067)。
  • 两组不良事件相似。

关键数值与推荐

  • 主要结局包括第0-28天抗生素疗程数(优效性)和第0-7天症状负担总分(非劣效性,界值125%)。

临床怎么用

  • 对于非复杂性尿路感染女性,不应以熊果叶提取物初始治疗替代磷霉素,因其症状负担更高且肾盂肾炎发生数数值上更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We explored whether initial treatment with the herbal drug uva ursi (UU) reduces antibiotic use in women with uncomplicated urinary tract infection (UTI) without increasing symptom burden and complication frequency compared with antibiotic treatment. METHODS: A double-blind randomized controlled trial was conducted in 42 family practices in Germany. The participants were adult women with suspected uncomplicated UTIs receiving either UU 105 mg 3 × 2 tablets for 5 days (intervention) or fosfomycin a 3-g single dose (control), and their respective placebos. Participants and investigators were blinded. The primary outcome included (1) antibiotic courses day 0-28 as superiority, and (2) symptom burden (sum of daily symptom scores) day 0-7, as non-inferiority outcome (margin 125%). Clinicaltrials.gov: NCT03151603. RESULTS: Overall, 398 patients were randomly allocated to groups receiving UU (n = 207) and fosfomycin (n = 191). The number of antibiotic courses was 63.6% lower (95% CI 53.6%-71.4%; p < 0.0001) in the UU group than in the fosfomycin group. The ratio of total symptom burden in the UU group compared with control was 136.5% (95% CI 122.7-151.9; p 0.95), failing non-inferiority. Eight women developed pyelonephritis in the UU group compared with two in the fosfomycin group (mean difference 2.8; 95% CI 0.2-5.9; p 0.067). Adverse events were similar between the groups. DISCUSSION: In women with uncomplicated UTIs, initial treatment with UU reduced antibiotic use but led to a higher symptom burden and more safety concerns than fosfomycin.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Gágyor I, Hummers E, Schmiemann G, et al. Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial. Clin Microbiol Infect. 2021. PMID: 34111592. doi:10.1016/j.cmi.2021.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。